Regeneron price target raised to $575 from $565 at BofA

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were “good,” but FY25 guidance was “not very useful” as guidance was provided for only expenses as usual, which is “not very helpful when pondering the negative impact biosimilar Eylea,” namely Amgen’s (AMGN) Pavblu, might have, the analyst tells investors. In the nearer-term, the firm thinks consensus EPS could be at risk from faster-than-expected Eylea erosion, the analyst added.